CEO Stock Option Grant at Pasithea Therapeutics Corp.

Tiago Marques, the Chief Executive Officer of Pasithea Therapeutics Corp., was granted 493,341 stock options on October 24, 2025. The options, which are exercisable at $0.715 per share, vest over three years, with 33% vesting after one year and the remainder in equal quarterly installments over the next two years. The options fully vest upon a Change in Control and can be exercised for up to three years following termination of service, except in cases of termination for Cause. This grant is part of the company's 2023 Stock Incentive Plan.